GABA Therapeutics

GABA Therapeutics is a clinical-stage biotechnology company focused on addressing the growing unmet medical needs of serious psychiatric and neurological disorders, including anxiety, depression, epilepsy, and rare diseases. The company’s team is developing GRX-917, a novel drug candidate with the potential for broad safety and efficacy across a wide range of therapeutic indications, aiming to transform the lives of patients suffering from life-altering neuropsychiatric, neurological, and pain disorders. Many of these conditions represent some of the largest unmet medical needs in the United States and worldwide.